Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 AbbVie Takes Another Step Toward Its Post-Humira Future
2 AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
3 Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors
4 Leerink Partners Stick to Their Buy Rating for AbbVie By Investing.com
5 Price Over Earnings Overview: AbbVie
6 AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains
7 AbbVie and More Companies That Are Expected to Raise Their Dividends
8 AbbVie Trade Secret Claims Fail at Pleading Stage for Lack of Jurisdiction
9 AbbVie plans product launches in India from global portfolio
10 Regeneron, Novo Nordisk, Lilly and AbbVie stake claims on September's list of top TV ad spenders
11 AbbVie Inc (ABBV) Stock: Do Analysts Think You Should Hold?
12 AbbVie Forms Flat Base Ahead Of Q3 Earnings Report
13 AbbVie (ABBV) stock forecast: Regulatory pressure mounting on the stock
14 AbbVie: Spotlight On Rinvoq Ahead Of Q3 Earnings
15 AbbVie Inc. stock underperforms Monday when compared to competitors
16 Why AbbVie Stock Sank in September
17 Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors' survey shows
18 Alvotech scores in AbbVie trade secrets case, but the Humira patent fight will stretch into next year
19 Implant maker AbbVie launches breast cancer campaign to highlight reconstruction options
20 Just Four Days Till AbbVie Inc. (NYSE:ABBV) Will Be Trading Ex-Dividend
21 AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts
22 In Humira kickbacks case, disgruntled AbbVie investors score class-action status
23 The Sham Litigation Exception after AbbVie
24 AbbVie Vs. Moderna Stock: Which Is The Better Buy?
25 3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market
26 AbbVie pressures Biohaven in migraine prevention with FDA approval for its CGRP blockbuster-to-be Qulipta
27 AbbVie: The Humira Situation Remains Scary
28 Is It Worth Considering AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend?
29 Federal Judge Dismisses AbbVie Trade Secrets Case Against Alvotech
30 AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
31 AbbVie Inc. stock rises Tuesday, still underperforms market
32 As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement
33 AbbVie Inc. stock outperforms market on strong trading day
34 AbbVie Is A Cheap Large Cap With New Drugs To Come
35 AbbVie Appears Ready To Reverse And Outperform
36 AbbVie Inc. stock falls Wednesday, underperforms market
37 Eli Lilly, AbbVie favorites at JPMorgan as big pharma set for Q3 earnings
38 FDA Approves AbbVie's Qulipta
39 AbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like Buffett
40 AbbVie Inc. stock outperforms competitors on strong trading day
41 AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains
42 Should You Buy AbbVie Inc (ABBV) Stock on Monday?
43 AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
44 Is AbbVie A Good Dividend Stock? Perceived Risks Offer Tremendous Value
45 Why you should buy AbbVie Inc. shares
46 AbbVie Inc. stock falls Monday, underperforms market
47 AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
48 AbbVie, industry group push for international compromise on when trial investigators should receive unblinded data
49 Will AbbVie Inc (ABBV) Stay at the Top of the Healthcare Sector?
50 AbbVie Inc. stock falls Tuesday, underperforms market
51 AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 14, 2021
52 AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021
53 AbbVie Inc. stock rises Thursday, still underperforms market
54 AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
55 Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness
56 AbbVie Inc. stock outperforms market despite losses on the day
57 AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains
58 Abbvie's Imbruvica patents echo Humira strategy
59 The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
60 AbbVie and REGENXBIO Announce Eye Care Collaboration
61 How Many AbbVie Inc. (NYSE:ABBV) Shares Do Institutions Own?
62 I-Mab in talks about deals, stake sale to build on $3B AbbVie alliance — Bloomberg
63 AbbVie's Trade Secrets Case Against Alvotech Tossed by Judge
64 AbbVie Says FDA Approves Qulipta as Migraine Treatment
65 Rinvoq Meets Primary Endpoints as Treatment for Active Ankylosing Spondylitis
66 AbbVie Stock: Price Seems Fair for Biopharmaceutical Play By TipRanks
67 Court Sides With Rival In AbbVie's Trade Secrets Suit
68 Oyster Point, with AbbVie and Novartis in its sights, wins first FDA approval for nasal spray to treat dry eye disease
69 AbbVie (ABBV) Stock Moves -0.33%: What You Should Know
70 Boehringer's interchangeable tag for Humira biosim is a 'landmark' win for the field: analyst
71 AbbVie's Rinvoq adds indications including atopic dermatitis < Pharma < 기사본문
72 Global Oncology Pharmaceuticals Market (2021 to 2026)
73 AbbVie Releases Additional Data on Rinvoq for Atopic Dermatitis
74 Australian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie
75 Pediatric Brain Tumor Market Size and Forecast | Key Companies – Abbott, AbbVie, Akorn, Agios, Baxter, Bayer, Epizyme, Novartis, Mylan , – The Host
76 Abbvie (ABBV) gains 0.32% in Light Trading on October 21
77 Alvotech Sees AbbVie's Humira Trade Secrets Case Thrown Out In US
78 Fill And Finish CMO Market Impact and Recovery Analysis| AbbVie, Argonaut, Symbiosis Pharmaceutical Services – Puck77
79 Antiviral Therapeutics Market Swot Analysis by Key Players AbbVie Inc., GSK, Boehringer Ingelheim – Puck77
80 Direct-acting Antiviral Drugs Market Future Growth Outlook 2021-2028 | AbbVie Inc., GSK, Boehringer Ingelheim – Puck77
81 Thyroid Disorder Therapy Market Top Players Sanofi, AbbVie Inc., Aspen, GlaxoSmithKline
82 Inhalation Anesthesia Market Future Growth Outlook 2021-2028 | AbbVie Inc., Baxter, Piramal Enterprises Limited – Puck77
83 AbbVie's atopic dermatitis drug RINVOQ gets Health Canada approval
84 Inhalational Anesthesia Drugs Market Is Booming Worldwide [Baxter, AbbVie, Piramal Enterprises]
85 Endometriosis Treatment Drugs Market to Witness Rapid Growth by 2028 | AbbVie Inc, Bayer AG, AstraZeneca – IMIESA
86 Disease-Modifying Antirheumatic Drug Market Size, Share 2021-2026: Overall Industry Analysis by Growth, Statistics, Trends, Demand, Overview, Forecast | AbbVie, Amgen, Pfizer, Roche Holding AG – The Host
87 AbbVie (ABBV) Scheduled to Post Quarterly Earnings on Friday
88 Autoimmune Disease Drug Market Analysis, Research Study With Abbott Laboratories, Pfizer, AbbVie – Puck77
89 Menopausal Hot Flashes Market Size, Growth 2028 | Key Companies – Bayer AG, AbbVie Inc. (Allergan PLC), Novartis AG, Pfizer, Novo Nordisk Corporation, Hisamitsu Pharmaceutical Co. – Puck77
90 AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of "Buy" by Brokerages
91 Global Immunology Market worth $156,378.2 million :
92 Breast Cancer Treatment Drugs Market Size and Forecast | Key Players – Abbvie, Abbott, Bristol-Myers Squibb, Novartis, Pfizer, – Puck77
93 In-Vitro Diagnostics (IVD) Devices Market Analysis 2021-2028 | Keyplayers AbbVie, Boehringer Ingelheim, Lonza, AMRI – Puck77
94 Testosterone Replacement Therapy Market Size and Forecast | Key Players – Abbvie, Endo International, Eli Lilly, Pfizer, Actavis (allergan), Bayer, Novartis, Teva, Mylan, Upsher-smith, – Puck77
95 Divalproex Sodium Market Size and Forecast | Key Players – AbbVie, Mylan, Aurobindo Pharma, Dr Reddys Labs, Zydus Pharms USA, Sun Pharm, LUPIN, Teva, Orchid, – Puck77
96 Biologics Drug Development Market Size and Forecast | Key Players – Abbvie, Allergan, Boehringer Ingelheim, Charles River Laboratories, Catalent, Lonza Group, Amgen, Sanofi, – Puck77
97 An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
98 Breast Cancer Diagnostic Technologies Market Size and Forecast | Key Players – Abbvie, Abbott, Bristol-Myers Squibb, Agilent Technologies, Novartis, Pfizer, – Puck77
99 Blood Cancer Therapeutics Market Size and Forecast | Key Players – AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Roche, Novartis, Boehringer Ingelheim, Pfizer, Sanofi, – Puck77
100 Pharmaceutical company AbbVie inflated prices for two major drugs, House Oversight report says